US Edition
SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types
- On May 26, 2025, SeekIn Inc. revealed the clinical validation of SeekInCare, an innovative multi-omics blood test developed in San Diego to identify a range of cancers at their initial stages.
- Detecting cancer early enhances the chances of successful treatment; however, many cases are identified only after the disease has progressed, highlighting the critical need for easy-to-access diagnostic tests.
- SeekInCare integrates genomic, epigenetic, and proteomic data using shallow whole-genome sequencing and AI to detect cancer broadly from a single 8ml blood draw.
- An analysis of 617 cancer patients and 580 controls in a retrospective study demonstrated a sensitivity of 60% with 98.3% specificity, while subsequent validation in a forward-looking study including 1,203 participants showed improved sensitivity of 70% at 95.2% specificity.
- SeekInCare demonstrates potential as a non-invasive, population-level screening tool particularly for high-risk groups, aiming to reduce cancer mortality rates by 15%.
15 Articles
15 Articles
MedPage Today
Anti-Aging, Acupuncture and Health NewsNew Blood Test for HPV+ Head and Neck Cancer Tops Existing Tests, Tissue Biopsy
(MedPage Today) -- An investigational blood test for human papillomavirus (HPV)-positive oropharyngeal cancer significantly outperformed current testing methods in a direct comparison involving patient blood samples. Based on whole-genome sequencing...
Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics
The multicancer early detection (MCED) test has the potential to enhance current cancer-screening methods. We evaluated a new MCED test that analyzes plasma cell-free DNA using genetic- and fragmentomics-based features from whole-genome sequencing. The present study included an internal validation cohort of 3,021 patients with cancer and 3,370 noncancer controls, and an independent cohort of 677 patients with cancer and 687 noncancer individuals…
The Billings Gazette
SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types
SAN DIEGO, May 26, 2025 /PRNewswire/ -- A groundbreaking study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare®, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types. Developed…
SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types - PressReach
SAN DIEGO, May 26, 2025 /PRNewswire/ — A groundbreaking study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare®, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types. Developed by researchers at SeekIn Inc., SeekInCare integrates advanced genomic, epigenetic, and proteomic analyses to identify cancer at its early stage, offering hope for i…
SeekIn announces clinical validation of multi-omics blood test in study
SeekIn has announced the clinical validation of its SeekInCare blood test, intended for the early identification of various types of cancer.The post SeekIn announces clinical validation of multi-omics blood test in study appeared first on Medical Device Network.
Shining a Light on Early Cancer Detection - Medika Life
Cancer that is diagnosed at an early stage, before it has grown and spread through the body, is more likely to be treated successfully. This means that detecting cancer quickly saves lives and there is an urgent need for earlier, accessible cancer detection globally. Usually, detecting cancer is done through a combination of physical exams, imaging tests, blood tests, and biopsies. A biopsy, where a tissue sample is taken and examined under a mi…
Coverage Details
Bias Distribution
- 86% of the sources are Center
To view factuality data please Upgrade to Premium
